Related Experiment Video
Updated: Feb 27, 2026
04:53
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
11.4K
Some remaining challenges regarding multiple endpoints in clinical trials.
1Amgen Inc., One Amgen Center Drive, 24-2-C, Thousand Oaks, CA, 91320, U.S.A.
Statistics in Medicine
|July 1, 2017
Summary
This study addresses ongoing challenges in clinical trial endpoint analysis, focusing on terminology, simultaneous superiority and non-inferiority testing, and multiplicity corrections. It also reviews the FDA
Area of Science:
- Clinical Trials Methodology
- Biostatistics
- Pharmaceutical Research
Background:
- Recent advancements in handling multiple endpoints in clinical trials have not fully resolved existing challenges.
- Ambiguity in terminology and lack of consensus on statistical approaches persist.
Purpose of the Study:
- To discuss key challenges in managing multiple endpoints in clinical trials.
- To examine the justification for simultaneous non-inferiority and superiority testing.
- To analyze the need for multiplicity corrections and appropriate statistical procedures.
Main Methods:
- Discussion of current challenges in multiple endpoint handling.
- Analysis of the FDA's draft guidance on Multiple Endpoints in Clinical Trials.
- Review of statistical methodologies for multiple comparisons.
Main Results:
- Identified confusion in terminology for multiple endpoints.
- Highlighted disagreements on when multiplicity corrections are necessary.
- Discussed the choice of appropriate multiple comparison procedures.
Conclusions:
- Despite advances, significant challenges remain in clinical trial endpoint management.
- The FDA's draft guidance offers a perspective on these complex issues.
- Further clarity and agreement are needed for robust clinical trial design.
More Related Videos
Related Concept Videos
01:16Clinical Trials
10.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.9K
01:11Clinical Trials: Overview
5.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.1K
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
286
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
286
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
503
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
503
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
192
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
192
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
197
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
197